Does Selinexor treat mantle cell lymphoma?

Mantle cell lymphoma (MCL)is a rare, incurableB-cell non-Hodgkin lymphoma. Selinexor (Selinexor) is in clinical development by Karyopharm Therapeutics and is currently in Phase II trials in mantle cell lymphoma. According to data from GlobalData, phase II drugs for the treatment of mantle cell lymphoma have a PTSR (Phase transition success rate) indication benchmark of 31% and can progress to phase III.

Both blastoid and classical mantle cell lymphoma cells are susceptible to the cytotoxic effects of selinesol, a well-established inhibitor of XPO1, manifested by loss of cell viability and induction of apoptosis. The addition of venetoclax (venetoclax) to selinexol showed synergistically reduced cell survival and increased cell death in blastoid and classic MCL cells compared with each single drug treatment. Selinesol or venetoclax treatment alone reduced MCL1 expression and increased BAX levels in MCL cells, and these effects were further enhanced by their combination regimen. Mechanistically, the study proved that the induction of DNA damage and the inactivation of the DNA damage response are related to the synergistic effect of the drug combination.

The original drug Seleniso has been launched in China, but it has not yet entered the scope of medical insurance. Specifications The price of 20mg*12 tablets per box may be around 20,000 yuan. The US version of the original Seleniso drug sold overseas, with a specification of 20mg*8 tablets, may cost more than 100,000 yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are also generic Selinisol drugs produced and marketed overseas. The price of a box of 20mg*16 tablets produced by a Lao pharmaceutical factory may be around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the original drugs sold domestically and abroad.